6,936
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Assessment of clinical outcomes of medicinal cannabis therapy for depression: analysis from the UK Medical Cannabis Registry

, , , , , , , , , , & ORCID Icon show all
Pages 995-1008 | Received 03 Aug 2022, Accepted 20 Dec 2022, Published online: 01 Jan 2023

Figures & data

Table 1. Baseline data about patient demographics and medical history (n = 129).

Table 2. Primary, secondary, and tertiary indications for cannabis-based medicinal products of study participants (n = 129).

Table 3. Median (IQR) baseline and follow-up scores for PHQ-9, GAD-7, SQS, EQ-5D-5L, and PGIC at 1, 3, and 6 months.

Figure 1. Box plots showing the change in PHQ-9 from baseline at 1, 3, and 6 months. Wilcoxon signed-rank tests were used for comparison between time intervals, *p < 0.050.

Figure 1. Box plots showing the change in PHQ-9 from baseline at 1, 3, and 6 months. Wilcoxon signed-rank tests were used for comparison between time intervals, *p < 0.050.

Table 4. Subgroup analysis of median (IQR) changes in PHQ-9 from baseline at 1, 3, and 6 months. Subgroups were compared using Mann-Whitney U tests.

Table 5. Adverse events recorded by participants (n = 129).